Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Sep:60:11-17.
doi: 10.1016/j.leukres.2017.05.002. Epub 2017 May 30.

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia

Srdan Verstovsek  1 , Stephane Courby  2 , Martin Griesshammer  3 , Ruben A Mesa  4 , Carrie Baker Brachmann  5 , Jun Kawashima  5 , Julia D Maltzman  5 , Lixin Shao  5 , Yan Xin  5 , Daniel Huang  6 , Ashish Bajel  7
Affiliations
Clinical Trial

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia

Srdan Verstovsek et al. Leuk Res. 2017 Sep.

Abstract

Momelotinib is a potent inhibitor of JAK1 and JAK2 that demonstrated efficacy in patients with primary and secondary myelofibrosis. This phase 2, open-label, randomized study evaluated the efficacy and safety of oral once-daily momelotinib (100mg and 200mg) for the treatment of polycythemia vera (PV) and essential thrombocythemia (ET). The primary endpoint for PV was overall response rate (ORR), defined as the proportion of patients with hematocrit <45%, white blood cell count <10×109/L, platelet count ≤400×109/L, and resolution of palpable splenomegaly, each lasting ≥4 weeks. The definition of ORR for ET excluded the hematocrit component. A total of 39 patients (28 PV, 11 ET) were enrolled, with 28 patients receiving ≥12 weeks of treatment. The study was terminated due to limited efficacy. Two patients (ORR 5.1%) met the primary efficacy endpoint (both PV 200mg). Predose plasma levels of momelotinib were stable over time. A total of 31 (79.5%) patients experienced momelotinib-related adverse events (AEs), the most frequent being headache (23.1%), dizziness (18.0%), somnolence (15.4%), nausea (15.4%), and fatigue (15.4%). Three patients experienced serious AEs (7.7%), with 1 considered related to momelotinib (dyspnea). Peripheral neuropathy occurred in 7 (17.9%) patients (4 PV, 3 ET).

Trial registration: ClinicalTrials.gov NCT01998828.

Keywords: Essential thrombocythemia; Momelotinib; Phase 2 study; Polycythemia vera.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Patient disposition. ET, essential thrombocythemia; PV, polycythemia vera.
Fig. 2.
Fig. 2.
Momelotinib plasma concentration over time by dose. ET, essential thrombocythemia; PV, polycythemia vera; Q1, first quartile; Q3, third quartile.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tefferi A, Vardiman JW, Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22 (2008) 14–22. - PubMed
    1. Tefferi A, Barbui T, Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management, Am. J. Hematol. 90 (2015) 162–173. - PubMed
    1. Mascarenhas J, Mughal TI, Verstovsek S, Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib, Curr. Med. Chem. 19 (2012) 4399–4413. - PMC - PubMed
    1. Alvarez-Larran A, Martinez-Aviles L, Hemandez-Boluda JC, Ferrer-Marin F, Antelo ML, Burgaleta C, et al., Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea, Ann. Hematol. 93 (2014) 2037–2043. - PubMed
    1. Alvarez-Larran A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernandez-Boluda JC, Ferrer-Marin F, et al., Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera, Blood 119 (2012) 1363–1369. - PubMed

Publication types

Associated data